Docetaxel-induced interstitial lung disease among patients with breast cancer: a case series and review of literature.

Taxane-induced pneumotoxicity is rare. However, 1-5% of patients taking docetaxel may develop severe pneumotoxicity. This has been limited to case reports in the literature.